1. Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D (1997) Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 24: S15
2. Alberts DS, Liu PY, Hanigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson D, Malviya VK, DuBeshter B, Adelson MD, Hoskins WJ (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1955
3. Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB (2002) Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!. J Clin Oncol 20: 3944–3946
4. Armstrong DK, Bundy BN, Baergen R, Lele SB, Copeland LJ, Walker J, Burger R (2002) Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172) (Abstract). Proc Am Soc Clin Oncol 21: 803
5. Baekelandt M, Lehne G, Trope CG, Szanto I, Pfeiffer P, Gustavson B, Kristensen GB (2001) Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol 19: 2983–2993